Folate Receptor Targeted Alpha-Therapy Using Terbium-149

Mostrar otras versiones (1)

Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (E(α) = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a (149)Tb-labeled DOTA-folate conjugate (cm09)...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Cristina, Reber, Josefine, Haller, Stephanie, Dorrer, Holger, Köster, Ulli, Johnston, Karl, Zhernosekov, Konstantin, Türler, Andreas, Schibli, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978496/
https://www.ncbi.nlm.nih.gov/pubmed/24633429
http://dx.doi.org/10.3390/ph7030353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978496/
https://www.ncbi.nlm.nih.gov/pubmed/24633429
http://dx.doi.org/10.3390/ph7030353

Ejemplares similares